You must log in to view this webinar.

Should We Measure Lipoprotein(a) and What Should We Do With the Results?

SPEAKER NAME /
CREDENTIALS

Samia Mora, MD, MHS

Time of Talk

45 minutes

Description:

This webcast will review how Lp(a), a genetically derived LDL-like-particle, can increase cardiovascular risk.

Learning Objectives

  1. To discuss prevalence, screening, and measurement of lipoprotein(a).
  2. To summarize the relationship of lipoprotein(a) with cardiometabolic risk.
  3. To discuss treatment strategies for high lipoprotein(a).

Disclosures:

Institutional research grant to the Brigham and Women’s Hospital from Atherotech Diagnostics (2018).

Quest Diagnostics measured Lp(a) in the JUPITER trial.

This enduring material activity, Should We Measure Lipoprotein(a) and What Should We Do With the Results?, has been reviewed and is acceptable for up to 1.0  prescribed credits by the American Academy of Family Physicians. Term of approval begins July 1, 2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.